2023
Examining sociodemographic correlates of opioid use, misuse, and use disorders in the All of Us Research Program.
Yeh H, Peltz-Rauchman C, Johnson C, Pawloski P, Chesla D, Waring S, Stevens A, Epstein M, Joseph C, Miller-Matero L, Gui H, Tang A, Boerwinkle E, Cicek M, Clark C, Cohn E, Gebo K, Loperena R, Mayo K, Mockrin S, Ohno-Machado L, Schully S, Ramirez A, Qian J, Ahmedani B. Examining sociodemographic correlates of opioid use, misuse, and use disorders in the All of Us Research Program. PLOS ONE 2023, 18: e0290416. PMID: 37594966, PMCID: PMC10437856, DOI: 10.1371/journal.pone.0290416.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidElectronic Health RecordsEthnicityHumansMaleOpioid-Related DisordersPopulation HealthConceptsOpioid use disorderOpioid usePrescription opioidsElectronic health recordsReduced oddsDiagnosis of OUDSociodemographic characteristicsPrevalence of OUDNonmedical useLifetime opioid useEHR dataNon-Hispanic white participantsImportant clinical informationNon-medical useLifetime prevalenceStreet opioidsHigher oddsOpioidsClinical informationUse disordersUs Research ProgramSociodemographic correlatesLogistic regressionPrevalenceHealth recordsFamily and personal history of cancer in the All of Us research program for precision medicine
Bruce L, Paul P, Kim K, Kim J, Keegan T, Hiatt R, Ohno-Machado L, Investigators O. Family and personal history of cancer in the All of Us research program for precision medicine. PLOS ONE 2023, 18: e0288496. PMID: 37459328, PMCID: PMC10351738, DOI: 10.1371/journal.pone.0288496.Peer-Reviewed Original ResearchCommon and rare variants associated with cardiometabolic traits across 98,622 whole-genome sequences in the All of Us research program
Wang X, Ryu J, Kim J, Ramirez A, Mayo K, Condon H, Vaitinadin N, Ohno-Machado L, Talavera G, Ellinor P, Lubitz S, Choi S. Common and rare variants associated with cardiometabolic traits across 98,622 whole-genome sequences in the All of Us research program. Journal Of Human Genetics 2023, 68: 565-570. PMID: 37072623, PMCID: PMC10524735, DOI: 10.1038/s10038-023-01147-z.Peer-Reviewed Original ResearchConceptsDiverse human populationsGenomic dataGene-based burden testsWhole genome sequencesRare variant analysisHuman populationQuantitative traitsBurden testsRare lossLociComplex diseasesGenetic associationVariant analysisFunction variantsCardiometabolic traitsRare variantsTraitsBiomedical researchGIGYF1VariantsNPR2ACANSequencePopulationLDLR
2022
Achieving a Representative Sample of Asian Americans in Biomedical Research Through Community-Based Approaches: Comparing Demographic Data in the All of Us Research Program With the American Community Survey
Randal F, Lozano P, Qi S, Maene C, Shah S, Mo Y, Ratsimbazafy F, Boerwinkle E, Cicek M, Clark C, Cohn E, Gebo K, Loperena R, Mayo K, Mockrin S, Ohno-Machado L, Schully S, Ramirez A, Aschebrook-Kilfoy B, Ahsan H, Lam H, Kim K. Achieving a Representative Sample of Asian Americans in Biomedical Research Through Community-Based Approaches: Comparing Demographic Data in the All of Us Research Program With the American Community Survey. Journal Of Transcultural Nursing 2022, 34: 59-67. PMID: 36398985, DOI: 10.1177/10436596221130796.Peer-Reviewed Original ResearchMeSH KeywordsAsianBiomedical ResearchEducational StatusHumansPopulation HealthSurveys and QuestionnairesUnited StatesInvestigation of hypertension and type 2 diabetes as risk factors for dementia in the All of Us cohort
Nagar S, Pemu P, Qian J, Boerwinkle E, Cicek M, Clark C, Cohn E, Gebo K, Loperena R, Mayo K, Mockrin S, Ohno-Machado L, Ramirez A, Schully S, Able A, Green A, Zuchner S, Jordan I, Meller R. Investigation of hypertension and type 2 diabetes as risk factors for dementia in the All of Us cohort. Scientific Reports 2022, 12: 19797. PMID: 36396674, PMCID: PMC9672061, DOI: 10.1038/s41598-022-23353-z.Peer-Reviewed Original ResearchConceptsAssociation of hypertensionPrevalence of dementiaType 2 diabetesRisk factorsUS populationRace/ethnicityHigh prevalenceLarge observational cohort studyMultivariable logistic regression modelRisk factor modificationObservational cohort studyT2D risk factorsInvestigation of hypertensionAssociation of T2DOdds of dementiaRace/ethnicity groupsAssociation of sexCross-sectional analysisLogistic regression modelsWorld Health OrganizationElectronic health recordsConcurrent hypertensionModifiable comorbiditiesCohort studyFinal cohortConcordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence
Miller C, Althoff K, Schlueter D, Anton-Culver H, Chen Q, Garbett S, Ratsimbazafy F, Thomsen I, Karlson E, Cicek M, Pinto L, Malin B, Ohno-Machado L, Williams C, Goldstein D, Kouame A, Ramirez A, Gebo K, Schully S. Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence. MSphere 2022, 7: e00257-22. PMID: 36173112, PMCID: PMC9599436, DOI: 10.1128/msphere.00257-22.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ViralCOVID-19HumansImmunoglobulin GPopulation HealthPrevalenceSARS-CoV-2Sensitivity and SpecificitySeroepidemiologic StudiesConceptsSARS-CoV-2 antibody concentrationsLow prevalenceVaccine availabilitySARS-CoV-2 enzyme-linked immunosorbent assayFalse positivityLow SARS-CoV-2 prevalenceSARS-CoV-2 IgG assaysSARS-CoV-2 IgG testSARS-CoV-2 IgG antibodiesSevere acute respiratory syndrome coronavirus 2Coronavirus disease 2019 prevalenceAcute respiratory syndrome coronavirus 2Antibody concentrationsSARS-CoV-2 testDifferent antigensRespiratory syndrome coronavirus 2SARS-CoV-2 prevalenceSyndrome coronavirus 2SARS-CoV-2 pandemicConcordant positive resultsConcordant negative resultsEnzyme-linked immunosorbent assayPositive resultsFuture pandemic preparednessConcordance of resultsAn Overview of Cancer in the First 315,000 All of Us Participants
Aschebrook-Kilfoy B, Zakin P, Craver A, Shah S, Kibriya M, Stepniak E, Ramirez A, Clark C, Cohn E, Ohno-Machado L, Cicek M, Boerwinkle E, Schully S, Mockrin S, Gebo K, Mayo K, Ratsimbazafy F, Sanders A, Shah R, Argos M, Ho J, Kim K, Daviglus M, Greenland P, Ahsan H, . An Overview of Cancer in the First 315,000 All of Us Participants. PLOS ONE 2022, 17: e0272522. PMID: 36048778, PMCID: PMC9436122, DOI: 10.1371/journal.pone.0272522.Peer-Reviewed Original ResearchEpidemiology of atrial fibrillation in the All of Us Research Program
Alonso A, Alam A, Kamel H, Subbian V, Qian J, Boerwinkle E, Cicek M, Clark C, Cohn E, Gebo K, Loperena-Cortes R, Mayo K, Mockrin S, Ohno-Machado L, Schully S, Ramirez A, Greenland P. Epidemiology of atrial fibrillation in the All of Us Research Program. PLOS ONE 2022, 17: e0265498. PMID: 35294480, PMCID: PMC8926244, DOI: 10.1371/journal.pone.0265498.Peer-Reviewed Original ResearchConceptsAtrial fibrillationNon-Hispanic whitesUs Research ProgramRisk factorsEpidemiology of AFIncidence of AFPresence of AFHigher body mass indexStudy of AFClinical risk factorsIncident atrial fibrillationCoronary heart diseaseBody mass indexElectronic health record dataMedical history dataMedical history surveyNon-Hispanic blacksHealth record dataAvailable EHR dataNon-Hispanic AsiansHeart failureStudy enrollmentMass indexEligible participantsMean age
2021
Geographic Variation in Obesity at the State Level in the All of Us Research Program
Clark C, Chandler P, Zhou G, Noel N, Achilike C, Mendez L, O’Connor G, Smoller J, Weiss S, Murphy S, Ommerborn M, Karnes J, Klimentidis Y, Jordan C, Hiatt R, Ramirez A, Loperena R, Mayo K, Cohn E, Ohno-Machado L, Boerwinkle E, Cicek M, Schully S, Mockrin S, Gebo K, Karlson E. Geographic Variation in Obesity at the State Level in the All of Us Research Program. Preventing Chronic Disease 2021, 18: e104. PMID: 34941480, PMCID: PMC8718125, DOI: 10.5888/pcd18.210094.Peer-Reviewed Original ResearchConceptsBody mass indexObesity prevalenceElectronic health recordsSevere obesityPrevalence estimatesParticipants' electronic health recordsObesity prevention strategiesNational population-based estimatesEHR dataPopulation-based estimatesOverall obesity prevalenceState-level geographic variationsPopulation health studiesUS participantsEnrollment visitMass indexObesity preventionHigh prevalenceHealth StudyPrecision health approachObesityPrevention strategiesUs Research ProgramLarge geographic variationsCohort dataAntibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020
Althoff K, Schlueter D, Anton-Culver H, Cherry J, Denny J, Thomsen I, Karlson E, Havers F, Cicek M, Thibodeau S, Pinto L, Lowy D, Malin B, Ohno-Machado L, Williams C, Goldstein D, Kouame A, Ramirez A, Roman A, Sharpless N, Gebo K, Schully S. Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020. Clinical Infectious Diseases 2021, 74: 584-590. PMID: 34128970, PMCID: PMC8384413, DOI: 10.1093/cid/ciab519.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ViralCOVID-19Enzyme-Linked Immunosorbent AssayHumansImmunoglobulin GPopulation HealthSARS-CoV-2Sensitivity and SpecificityConceptsEnzyme-linked immunosorbent assayBlood specimensSARS-CoV-2 enzyme-linked immunosorbent assaySARS-CoV-2 immunoglobulin G (IgG) antibodiesSARS-CoV-2 antibodiesIgG enzyme-linked immunosorbent assayConfidence intervalsImmunoglobulin G antibodiesSARS-CoV-2Sequential testing algorithmEUROIMMUN assaysSymptomatic patientsTesting algorithmStudy visitG antibodiesCommunity transmissionTravel historyStudy participantsUS epidemicEarly weeksImmunosorbent assayTesting capacityAntibodiesWeeksUS states